Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


04.04.2022

1 ACS Appl Bio Mater
1 Aktuelle Urol
1 Analyst
2 Arch Ital Urol Androl
1 Artif Intell Med
1 Biochem Genet
1 Bioengineered
1 BMC Cancer
1 BMC Urol
1 BMJ Case Rep
1 Br J Cancer
3 Clin Cancer Res
1 Clin Genitourin Cancer
1 Clin Transl Oncol
1 Environ Toxicol Pharmacol
1 Eur Radiol
2 Eur Urol
3 Eur Urol Focus
1 Exp Ther Med
1 Front Mol Biosci
1 Future Oncol
1 Int J Infect Dis
1 Int J Urol
1 Int Urol Nephrol
1 J Am Acad Dermatol
1 J Enzyme Inhib Med Chem
1 J Immunol Res
2 J Immunother Cancer
1 J Med Case Rep
1 J Robot Surg
1 J Sex Med
1 Minerva Urol Nephrol
1 Mol Imaging Biol
1 Mol Med
1 Nat Rev Urol
1 Oncoimmunology
1 Pathol Res Pract
1 R I Med J (2013)
1 Radiother Oncol
1 Rofo
1 Sci Rep
1 Ther Adv Urol
1 Tissue Cell
2 Urol Oncol
1 Vet Comp Oncol
1 Vet Radiol Ultrasound


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    ACS Appl Bio Mater

  1. SAMADDAR S, Mazur J, Sargent J, Thompson DH, et al
    Immunostimulatory Response of RWFV Peptide-Targeted Lipid Nanoparticles on Bladder Tumor Associated Cells.
    ACS Appl Bio Mater. 2021;4:3178-3188.
    PubMed         Abstract available


    Aktuelle Urol

  2. MALLY D, Pfister D, Heidenreich A, Albers P, et al
    [Does robotic radical cystectomy affect oncological outcomes in bladder cancer patients?]
    Aktuelle Urol. 2022;53:153-158.
    PubMed         Abstract available


    Analyst

  3. FAN W, Xiong Q, Ge Y, Liu T, et al
    Identifying the grade of bladder cancer cells using microfluidic chips based on impedance.
    Analyst. 2022 Mar 28. doi: 10.1039/d2an00026.
    PubMed         Abstract available


    Arch Ital Urol Androl

  4. THANGAVELU M, Ismail A, Zakaria A, Elmansy H, et al
    Aristolochic acid: What urologists should know.
    Arch Ital Urol Androl. 2022;94:123-125.
    PubMed         Abstract available

  5. MEHRNOUSH V, Keramati S, Ismail A, Shabana W, et al
    Adverse pathological outcomes of patients with de novo muscle invasive bladder cancer in Northern Ontario.
    Arch Ital Urol Androl. 2022;94:41-45.
    PubMed         Abstract available


    Artif Intell Med

  6. FREITAS NR, Vieira PM, Cordeiro A, Tinoco C, et al
    Detection of bladder cancer with feature fusion, transfer learning and CapsNets.
    Artif Intell Med. 2022;126:102275.
    PubMed         Abstract available


    Biochem Genet

  7. WU X, Cao W, Lu C, Zuo L, et al
    circ3323 Motivates Host Gene to Promote the Aggressiveness of Bladder Cancer.
    Biochem Genet. 2022 Apr 1. pii: 10.1007/s10528-022-10210.
    PubMed         Abstract available


    Bioengineered

  8. ZHANG X, Xiong H, Zhao Y, Lin S, et al
    Circular RNA LONP2 regulates proliferation, invasion, and apoptosis of bladder cancer cells by sponging microRNA-584-5p.
    Bioengineered. 2022;13:8823-8835.
    PubMed         Abstract available


    BMC Cancer

  9. WU Z, Xia C, Zhang C, Yang D, et al
    Prognostic significance of SNCA and its methylation in bladder cancer.
    BMC Cancer. 2022;22:330.
    PubMed         Abstract available


    BMC Urol

  10. LI K, Yang X, Zhuang J, Cai L, et al
    External validation of Pentafecta in patients undergoing laparoscopic radical cystectomy: results from a high-volume center.
    BMC Urol. 2022;22:41.
    PubMed         Abstract available


    BMJ Case Rep

  11. KITAMURA K, Isotani S, Muto S, Horie S, et al
    Efficacy of pembrolizumab in a rare type of bladder cancer arising 25 years after augmentation cystoplasty.
    BMJ Case Rep. 2022;15.
    PubMed         Abstract available


    Br J Cancer

  12. LETT L, George M, Slater R, De Lacy Costello B, et al
    Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.
    Br J Cancer. 2022 Mar 29. pii: 10.1038/s41416-022-01785.
    PubMed         Abstract available


    Clin Cancer Res

  13. CHU CE, Sjostrom M, Egusa EA, Gibb EA, et al
    Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
    Clin Cancer Res. 2021;27:5123-5130.
    PubMed         Abstract available

  14. KOUTROS S, Rao N, Moore LE, Nickerson ML, et al
    Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.
    Clin Cancer Res. 2021;27:3725-3733.
    PubMed         Abstract available

  15. WANG L, Sfakianos JP, Beaumont KG, Akturk G, et al
    Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
    Clin Cancer Res. 2021;27:4287-4300.
    PubMed         Abstract available


    Clin Genitourin Cancer

  16. TAGUCHI S, Watanabe M, Tambo M, Machida H, et al
    Proposal for a New Vesical Imaging-Reporting and Data System (VI-RADS)-Based Algorithm for the Management of Bladder Cancer: A Paradigm Shift From the Current Transurethral Resection of Bladder Tumor (TURBT)-Dependent Practice.
    Clin Genitourin Cancer. 2022 Mar 4. pii: S1558-7673(22)00047.
    PubMed         Abstract available


    Clin Transl Oncol

  17. VALDERRAMA BP, Gonzalez-Del-Alba A, Morales-Barrera R, Pelaez Fernandez I, et al
    SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).
    Clin Transl Oncol. 2022 Mar 26. pii: 10.1007/s12094-022-02815.
    PubMed         Abstract available


    Environ Toxicol Pharmacol

  18. YU K, Du Z, Xuan H, Chen Q, et al
    Comprehensive analysis based in silico study of organophosphate flame retardants - environmental explanation of bladder cancer progression.
    Environ Toxicol Pharmacol. 2022;92:103851.
    PubMed         Abstract available


    Eur Radiol

  19. YE L, Chen Y, Xu H, Xie H, et al
    Biparametric magnetic resonance imaging assessment for detection of muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Eur Radiol. 2022 Apr 1. pii: 10.1007/s00330-022-08696.
    PubMed         Abstract available


    Eur Urol

  20. MAYR R, Eckstein M, Wirtz RM, Santiago-Walker A, et al
    Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guerin Immunotherapy.
    Eur Urol. 2022 Mar 26. pii: S0302-2838(22)01670.
    PubMed         Abstract available

  21. ALFRED WITJES J
    Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01786.
    PubMed        


    Eur Urol Focus

  22. DELL'OGLIO P, Mazzone E, Lambert E, Vollemaere J, et al
    The Effect of Surgical Experience on Perioperative and Oncological Outcomes After Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Evidence from a Referral Centre with Extensive Experience in Robotic Surgery.
    Eur Urol Focus. 2021;7:352-358.
    PubMed         Abstract available

  23. OURFALI S, Ohannessian R, Fassi-Fehri H, Pages A, et al
    Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guerin Connaught Strain for Bladder Cancer Patients.
    Eur Urol Focus. 2021;7:111-116.
    PubMed         Abstract available

  24. DANCIK GM, Theodorescu D
    Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314.
    Eur Urol Focus. 2022 Mar 23. pii: S2405-4569(22)00067.
    PubMed         Abstract available


    Exp Ther Med

  25. ZHOU W, He L, Dai Y, Zhang Y, et al
    MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer.
    Exp Ther Med. 2022;23:312.
    PubMed         Abstract available


    Front Mol Biosci

  26. YUAN S, Zhai Y, Tao T, Zhang X, et al
    Conflicting Roles of ZFP36L1 in Regulating the Progression of Muscle Invasive Bladder Cancer.
    Front Mol Biosci. 2022;9:687786.
    PubMed         Abstract available


    Future Oncol

  27. RIZZO A, Mollica V, Santoni M, Ricci AD, et al
    Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.
    Future Oncol. 2022;18:739-748.
    PubMed         Abstract available


    Int J Infect Dis

  28. NIELENS N, Marot L, Baeck M
    Sporotrichoid distributed tuberculous panniculitis as a late complication of intravesical bacillus Calmette-Guerin (BCG) immunotherapy.
    Int J Infect Dis. 2022;117:247-250.
    PubMed         Abstract available


    Int J Urol

  29. NASELLI A, Pirola GM
    Editorial Comment from Dr Naselli and Dr Pirola to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Mar 31. doi: 10.1111/iju.14883.
    PubMed        


    Int Urol Nephrol

  30. KAWADA T
    Serum irisin concentration in patients with bladder cancer.
    Int Urol Nephrol. 2022 Apr 1. pii: 10.1007/s11255-022-03199.
    PubMed        


    J Am Acad Dermatol

  31. HIROTSU KE, Rana J, Wang JY, Raghavan SS, et al
    Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
    J Am Acad Dermatol. 2021;85:1610-1611.
    PubMed        


    J Enzyme Inhib Med Chem

  32. LIU J, Zhu X, Yu L, Mao M, et al
    Discovery of novel sulphonamide hybrids that inhibit LSD1 against bladder cancer cells.
    J Enzyme Inhib Med Chem. 2022;37:866-875.
    PubMed         Abstract available


    J Immunol Res

  33. CHEN C, Shang A, Sun Z, Gao Y, et al
    Urinary Exosomal Long Noncoding RNA TERC as a Noninvasive Diagnostic and Prognostic Biomarker for Bladder Urothelial Carcinoma.
    J Immunol Res. 2022;2022:9038808.
    PubMed         Abstract available


    J Immunother Cancer

  34. ZHANG Y, Huo F, Cao Q, Jia R, et al
    FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer.
    J Immunother Cancer. 2022;10.
    PubMed         Abstract available

  35. KAWAI T, Taguchi S, Nakagawa T, Kamei J, et al
    Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis.
    J Immunother Cancer. 2022;10.
    PubMed         Abstract available


    J Med Case Rep

  36. OKA T, Matsuzaki K, Izumi H, Nonomura D, et al
    Osteosarcoma of the bladder: a case report.
    J Med Case Rep. 2022;16:118.
    PubMed         Abstract available


    J Robot Surg

  37. SASAKI Y, Takahashi M, Fukuta K, Shiozaki K, et al
    The patient-side surgeon plays a key role in facilitating robot-assisted intracorporeal ileal conduit urinary diversion in men.
    J Robot Surg. 2022;16:437-444.
    PubMed         Abstract available


    J Sex Med

  38. LOUAR M, Morel-Journel N, Ruffion A, Carnicelli D, et al
    Female Sexual Function and Body Image After Urinary Diversion for Benign Conditions.
    J Sex Med. 2022;19:263-269.
    PubMed         Abstract available


    Minerva Urol Nephrol

  39. VECCIA A, Carbonara U, Derweesh I, Mehrazin R, et al
    Single-stage Xi(R) robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes.
    Minerva Urol Nephrol. 2022;74:233-241.
    PubMed         Abstract available


    Mol Imaging Biol

  40. NOVRUZOV E, Dendl K, Ndlovu H, Choyke PL, et al
    Head-to-head Intra-individual Comparison of [(68)Ga]-FAPI and [(18)F]-FDG PET/CT in Patients with Bladder Cancer.
    Mol Imaging Biol. 2022 Mar 29. pii: 10.1007/s11307-022-01715.
    PubMed         Abstract available


    Mol Med

  41. MOISOIU T, Dragomir MP, Iancu SD, Schallenberg S, et al
    Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer.
    Mol Med. 2022;28:39.
    PubMed         Abstract available


    Nat Rev Urol

  42. TEOH JY, Kamat AM, Black PC, Grivas P, et al
    Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.
    Nat Rev Urol. 2022 Mar 31. pii: 10.1038/s41585-022-00578.
    PubMed         Abstract available


    Oncoimmunology

  43. GUALLAR-GARRIDO S, Campo-Perez V, Perez-Trujillo M, Cabrera C, et al
    Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-gamma/IL-17 release in bladder cancer treatment.
    Oncoimmunology. 2022;11:2051845.
    PubMed         Abstract available


    Pathol Res Pract

  44. KADKHODA S, Ghafouri-Fard S
    Function of miRNA-145-5p in the pathogenesis of human disorders.
    Pathol Res Pract. 2022;231:153780.
    PubMed         Abstract available


    R I Med J (2013)

  45. TRAN TML, Abdelrahman H, Tran C, Abraham R, et al
    A Curious Case of Hypercalcemia.
    R I Med J (2013). 2022;105:39-41.
    PubMed         Abstract available


    Radiother Oncol

  46. ASTROM LM, Behrens CP, Calmels L, Sjostrom D, et al
    Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: initial experience and dosimetric benefits.
    Radiother Oncol. 2022 Mar 28. pii: S0167-8140(22)00152.
    PubMed         Abstract available


    Rofo

  47. BROSE A, Krombach GA, Roller FC

    Rofo. 2022;194:205-207.
    PubMed        


    Sci Rep

  48. XU T, Junge JA, Delfarah A, Lu YT, et al
    Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time.
    Sci Rep. 2022;12:5518.
    PubMed         Abstract available


    Ther Adv Urol

  49. GRUNEWALD CM, Feldmeier V, Supprian T, Albers P, et al
    Cognitive function in patients undergoing cystectomy for bladder cancer - results from a prospective observational study.
    Ther Adv Urol. 2022;14:17562872221087660.
    PubMed         Abstract available


    Tissue Cell

  50. ZHANG L, Shao G, Shao J, Zhao J, et al
    PRMT5-activated c-Myc promote bladder cancer proliferation and invasion through up-regulating NF-kappaB pathway.
    Tissue Cell. 2022;76:101788.
    PubMed         Abstract available


    Urol Oncol

  51. DURSUN F, Elshabrawy A, Wang H, Wu S, et al
    Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy.
    Urol Oncol. 2022 Mar 26. pii: S1078-1439(22)00039.
    PubMed         Abstract available

  52. BUAC NP, Khusid JA, Sturgis MR, Gupta M, et al
    Disparities in patient and system factors explain racial/ethnic disparities in delayed time to treatment in muscle invasive bladder cancer.
    Urol Oncol. 2022 Mar 23. pii: S1078-1439(22)00060.
    PubMed         Abstract available


    Vet Comp Oncol

  53. DE BROT S, Lothion-Roy J, Grau-Roma L, White E, et al
    Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component.
    Vet Comp Oncol. 2022;20:38-49.
    PubMed         Abstract available


    Vet Radiol Ultrasound

  54. HENG HG, Ramos-Vara JA, Fulkerson CM, Fourez LM, et al
    Ultrasonographic detection of apex nodules in the urinary bladder of Scottish Terriers.
    Vet Radiol Ultrasound. 2022;63:234-239.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: